OS Advantage of Gotistobart Over Docetaxel in Patients with anti-PD‑(L)1- and Chemotherapy-Resistant Metastatic Squamous NSCLC By Ogkologos - April 14, 2026 11 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the stage 1 of the phase III PRESERVE-003 study Source RELATED ARTICLESMORE FROM AUTHOR Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer MOST POPULAR What Are Drug Shortages and How Can They Impact Care for... June 23, 2023 EMA Recommends Extension of Therapeutic Indications for Olaparib to Patients with... July 17, 2024 EMA Recommends Granting a Conditional Marketing Authorisation for Futibatinib April 28, 2023 The Evidence Is In: COVID Vaccines Do Protect Patients With Cancer... September 20, 2021 Load more HOT NEWS TRACERx EVO, a new programme to transform lung cancer research Opinion: ‘We need to increase testing in primary care’ Phase II LCMC3 Study of Neoadjuvant Atezolizumab Met Primary Endpoint with... COVID-19: “The really hard part is we know what needs to...
